HomeMarkets Markets Win For Pfizer? Seagen’s Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study By news August 17, 2023 0 175 FacebookTwitterPinterestWhatsApp Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected149,472FansLike396,312FollowersFollow2,650SubscribersSubscribe Latest Articles Markets Fall Back Friday – February Ending on a Week Note? Markets AI “hot takes” are becoming a market risk Markets How Trump’s renewed tariff chaos will stifle investment around the world Markets Netflix Backs Out of Bid for Warner Bros., Paving Way for an Ellison Takeover Markets Anthropic Takes a Stand Markets A Modest Proposal For Solving the AI Energy Crisis Markets Thursday Thrust: One Stock to Rule Us All (NVDA, of course!) Markets AI’s growing appetite for power is putting Pennsylvania’s aging electricity grid to the test Markets Epstein Files Are Missing Records About Woman Who Made Claim Against Trump Market News Violent aftermath of Mexico’s ‘El Mencho’ killing follows pattern of other high‑profile cartel hits AI Nvidia’s Quarterly Profit Hits $43 Billion on Strong A.I. Chip Sales Markets ⚡ Powering the AI Boom: Data Centers and Ratepayer Protection Pledge (SCAM!!!) Markets PhilStockWorld Top Trade Alert – Feb 25th, 2026 – HP, Inc. (HPQ) Markets Whiplash Wednesday – Back in Black for the Week Load more